Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer

NCT01560923 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

47

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Prostate Cancer

Interventions

BIOLOGICAL: Indoximod
BIOLOGICAL: Sipuleucel-T
OTHER: Placebo

Sponsor

Masonic Cancer Center, University of Minnesota